Anticoagulants Market
Anticoagulants Market Analysis By Drug Class (Factor X Inhibitor (NOAC/DOAC) Anticoagulants, Heparin Anticoagulants, Direct Thrombin Inhibitor Anticoagulants, Vitamin K Antagonist Anticoagulants), By Route of Administration, By Indication - Global Market Insights 2021 to 2031
Analysis of Anticoagulants market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
- FACT4335MR
- 25 Oct 2021
- Healthcare
- 170 Pages
- 30 Tables
- 83 Figures
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Market
- 4. Market Overview
- 5. Market Outlook
- 6. Global Market Analysis and Forecast, by Route of Administration
- 6.1. Oral
- 6.2. Injectable
- 7. Global Market Analysis and Forecast, by Drug Class
- 7.1. Factor XA Inhibitors (NOAC/DOAC)
- 7.2. Heparins
- 7.3. Direct Thrombin Inhibitors
- 7.4. Vitamin K Antagonists
- 8. Global Market Analysis and Forecast, by Indication
- 8.1. Deep Vein Thrombosis
- 8.2. Pulmonary Embolism
- 8.3. Atrial Fibrillation & Heart Attack
- 8.4. Others
- 9. Global Market Analysis and Forecast, by Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Online Pharmacies
- 10. Global Market Analysis and Forecast, by Region
- 10.1. North America
- 10.2. Europe
- 10.3. Asia Pacific
- 10.4. Latin America
- 10.5. Middle East & Africa
- 11. North America Market Analysis and Forecast
- 12. Europe Market Analysis and Forecast
- 13. Asia Pacific Market Analysis and Forecast
- 14. Latin America Market Analysis and Forecast
- 15. Middle East & Africa Market Analysis and Forecast
- 16. Competition Landscape
- 16.1. Bayer AG
- 16.2. Boehringer Ingelheim International GmbH
- 16.3. Bristol-Myers Squibb Company
- 16.4. Daiichi Sankyo Company, Limited
- 16.5. Sanofi
- 16.6. Johnson & Johnson Services
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 02: Global Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 03: Global Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 04: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 05: Global Market Size (US$ Mn) and Volume (Units) Forecast, by Region, 2021 to 2031
Table 06: North America Market Value (US$ Mn) Forecast, by Country, 2016 to 2031
Table 07: North America Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 08: North America Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 09: North America Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 10: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 11: Europe Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 12: Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 13: Europe Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 14: Europe Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 15: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 16: Asia Pacific Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 17: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 18: Asia Pacific Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 19: Asia Pacific Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 20: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 21: Latin America Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 22: Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 23: Latin America Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 24: Latin America Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 25: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 26: Middle East & Africa Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 27: Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 28: Middle East & Africa Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 29: Middle East & Africa Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 30: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
List Of Figures
Figure 01: Global Market Size Value (US$ Mn) Forecast, 2016 to 2031
Figure 02: Global Market Value Share (%), by Route of Administration, 2021
Figure 03: Global Market Value Share (%), by Drug Class, 2021
Figure 04: Global Market Value Share (%), by End-user, 2021
Figure 05: Global Market Value Share (%), by Region, 2021
Figure 06: Global Market Value Share, by Route of Administration, 2021 and 2031
Figure 07: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2016 to 2031
Figure 08: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Injectables, 2016 to 2031
Figure 09: Global Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 10: Global Market Value Share, by Drug Class, 2021 and 2031
Figure 11: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Factor XA Inhibitors, 2016 to 2031
Figure 12: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Heparins, 2016 to 2031
Figure 13: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Direct Thrombin Inhibitors, 2016 to 2031
Figure 14: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Vitamin K Antagonists, 2016 to 2031
Figure 15: Global Market Attractiveness, by Drug Class, 2021 to 2031
Figure 16: Global Market Value Share, by Indication, 2021 and 2031
Figure 17: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Deep Vein Thrombosis (DVT), 2016 to 2031
Figure 18: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pulmonary Embolism (PE), 2016 to 2031
Figure 19: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Atrial Fibrillation & Heart Attack, 2016 to 2031
Figure 20: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016 to 2031
Figure 21: Global Market Attractiveness, by Indication, 2021 to 2031
Figure 22: Global Market Value Share, by Distribution Channel, 2021 and 2031
Figure 23: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals Pharmacies, 2016 to 2031
Figure 24: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2016 to 2031
Figure 25: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016 to 2031
Figure 26: Global Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 27: Global Market Value Share Analysis, by Region, 2021 and 2031
Figure 28: Global Market Attractiveness Analysis, by Region, 2021 and 2031
Figure 29: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 30: North America Market Value Share, by Country, 2021 and 2031
Figure 31: North America Market Attractiveness, by Country, 2021 to 2031
Figure 32: North America Market Value Share, by Route of Administration, 2021 and 2031
Figure 33: North America Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 34: North America Market Value Share, by Drug Class, 2021 and 2031
Figure 35: North America Market Attractiveness, by Drug Class, 2021 to 2031
Figure 36: North America Market Value Share, by Indication, 2021 and 2031
Figure 37: North America Market Attractiveness, by Indication, 2021 to 2031
Figure 38: North America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 39: North America Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 40: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 41: Europe Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 42: Europe Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 43: Europe Market Value Share, by Route of Administration, 2021 and 2031
Figure 44: Europe Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 45: Europe Market Value Share, by Drug Class, 2021 and 2031
Figure 46: Europe Market Attractiveness, by Drug Class, 2021 to 2031
Figure 47: Europe Market Value Share, by Indication, 2021 and 2031
Figure 48: Europe Market Attractiveness, by Indication, 2021 to 2031
Figure 49: Europe Market Value Share, by Distribution Channel, 2021 and 2031
Figure 50: Europe Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 51: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 52: Asia Pacific Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 53: Asia Pacific Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 54: Asia Pacific Market Value Share, by Route of Administration, 2021 and 2031
Figure 55: Asia Pacific Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 56: Asia Pacific Market Value Share, by Drug Class, 2021 and 2031
Figure 57: Asia Pacific Market Attractiveness, by Drug Class, 2021 to 2031
Figure 58: Asia Pacific Market Value Share, by Indication, 2021 and 2031
Figure 59: Asia Pacific Market Attractiveness, by Indication, 2021 to 2031
Figure 60: Asia Pacific Market Value Share, by Distribution Channel, 2021 and 2031
Figure 61: Asia Pacific Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 62: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 63: Latin America Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 64: Latin America Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 65: Latin America Market Value Share, by Route of Administration, 2021 and 2031
Figure 66: Latin America Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 67: Latin America Market Value Share, by Drug Class, 2021 and 2031
Figure 68: Latin America Market Attractiveness, by Drug Class, 2021 to 2031
Figure 69: Latin America Market Value Share, by Indication, 2021 and 2031
Figure 70: Latin America Market Attractiveness, by Indication, 2021 to 2031
Figure 71: Latin America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 72: Latin America Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 73: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 74: Middle East & Africa Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 75: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 76: Middle East & Africa Market Value Share, by Route of Administration, 2021 and 2031
Figure 77: Middle East & Africa Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 78: Middle East & Africa Market Value Share, by Drug Class, 2021 and 2031
Figure 79: Middle East & Africa Market Attractiveness, by Drug Class, 2021 to 2031
Figure 80: Middle East & Africa Market Value Share, by Indication, 2021 and 2031
Figure 81: Middle East & Africa Market Attractiveness, by Indication, 2021 to 2031
Figure 82: Middle East & Africa Market Value Share, by Distribution Channel, 2021 and 2031
Figure 83: Middle East & Africa Market Attractiveness, by Distribution Channel, 2021 to 2031
Anticoagulants Market